Cargando…
Axitinib for the Management of Metastatic Renal Cell Carcinoma
In recent years, targeted agents have changed the treatment landscape for patients with advanced renal cell carcinoma (RCC), greatly improving treatment outcomes. Several targeted agents are now licensed for the treatment of metastatic RCC (mRCC), and a number of new agents are under investigation....
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585900/ https://www.ncbi.nlm.nih.gov/pubmed/21679004 http://dx.doi.org/10.2165/11591240-000000000-00000 |